Sensei Biotherapeutics Stock Jumps 230% on Faeth Acquisition and $200M Financing
Sensei Biotherapeutics acquired Faeth Therapeutics, adding lead asset PIKTOR to its pipeline and secured a $200 million private placement to finance its Phase 2 endometrial cancer trial and a Phase 1b breast cancer study by year-end 2026. Shares surged 230% to $30.12, marking a new 52-week high following the deal announcement.
1. Acquisition of Faeth Therapeutics
Sensei Biotherapeutics has completed its acquisition of Faeth Therapeutics, incorporating PIKTOR, an all-oral PI3K/AKT/mTOR pathway inhibitor targeting solid tumors, into its drug development portfolio.
2. Concurrent $200 Million Private Placement
The company secured a $200 million private placement to advance PIKTOR through key clinical milestones, including a Phase 2 trial in advanced endometrial cancer and a planned Phase 1b trial in HR+/HER2- breast cancer by year-end 2026, with remaining funds allocated to general corporate purposes and solnerstotug development.
3. Clinical Development Outlook
Integration of PIKTOR accelerates Sensei’s oncology strategy by adding a novel oral combination therapy to its pipeline, aiming for clinical data readouts in endometrial and breast cancer while maintaining progress on its ongoing Phase 1/2 solnerstotug trial.
4. Stock Market Reaction
Following the transaction announcement, Sensei’s shares rallied 230%, reaching $30.12 and setting a new 52-week high, reflecting strong investor confidence despite mixed technical indicators such as a neutral RSI and bearish MACD signals.